RGNX — REGENXBIO Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1590877 ·
Last close
$6.31
Market Cap
$326.21M
52W High
$11.36
52W Low
$5.45
ADV30
1,501,400
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 6,393,000 | -4,681,000 | -83,362,000 | -90,051,000 | 341,894,000 | 15,229,000 | 320,812,000 |
| Dec 2025 | 30,337,000 | 24,409,000 | -57,636,000 | -67,149,000 | 453,032,000 | 34,466,000 | 350,299,000 |
| Sep 2025 | 29,733,000 | 24,008,000 | -52,411,000 | -61,941,000 | 525,203,000 | 58,802,000 | 363,751,000 |
| Jun 2025 | 21,359,000 | 16,150,000 | -63,278,000 | -70,871,000 | 581,027,000 | 79,558,000 | 367,348,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-123,963,000
Investing CF
$-15,868,000
Financing CF
$116,771,000
CapEx
$-2,414,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.76
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,126,027,000
Inventory
—
Receivables
$27,383,000
ST Investments
$195,604,000
EBIT TTM
$-148,870,000
Pretax Income TTM
$-193,878,000
Interest Exp TTM
$45,008,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$87,822,000
EBITDA
$-241,170,000
Free Cash Flow
$-138,978,624
Enterprise Value
$424,116,992
Total Cash
$150,491,008
Total Debt
$248,396,000
Shares Out
51,697,621
Trailing EPS
$-5.60
Book Value
$0.41
ROE
-196.4%
ROA
-38.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,441,000 | -161,198,000 | -193,878,000 | 453,032,000 | 350,299,000 | — | -123,963,000 |
| Dec 2024 | 83,328,000 | -231,245,000 | -227,102,000 | 465,989,000 | 206,338,000 | — | -173,125,000 |
| Dec 2023 | 90,242,000 | -268,128,000 | -263,494,000 | 573,970,000 | 262,228,000 | — | -218,407,000 |
| Dec 2022 | 112,724,000 | -262,876,000 | -280,321,000 | 833,268,000 | 317,073,000 | — | -207,488,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.52
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IVVD | Invivyd, Inc. | $324.07M | $1.10 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $321.59M | $1.29 | — |
| NMRA | Neumora Therapeutics, Inc. | $340.92M | $1.84 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $343.55M | $9.89 | — |
| PALI | PALISADE BIO, INC. | $345.42M | $1.99 | — |
News headlines (Yahoo Finance, 1h cache)
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway
2026-05-20 12:35 · Yahoo
REGENXBIO to Participate in Upcoming Investor Conferences
2026-05-18 20:05 · Yahoo
Regenxbio (RGNX) Q1 2026 Earnings Transcript
2026-05-18 13:06 · Yahoo
Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ...
2026-05-14 23:03 · Yahoo
Update: Regenxbio Shares Fall After Q1 Swings to Loss, Revenue Declines; Phase 3 Study of RGX-202 Meets Primary Endpoint
2026-05-14 18:39 · Yahoo
Regenxbio Shares Rise After Positive Duchenne Trial Results
2026-05-14 14:09 · Yahoo
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-14 12:30 · Yahoo
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights
2026-05-14 11:10 · Yahoo
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
2026-05-14 11:00 · Yahoo
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
2026-05-14 09:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.